{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Non+Hodgkin+Lymphoma&page=4", "query": { "condition": "B-cell Non Hodgkin Lymphoma", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 2213, "total_pages": 222, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Non+Hodgkin+Lymphoma&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Non+Hodgkin+Lymphoma&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T19:40:29.135Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03888105", "title": "A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-cell Non-Hodgkin Lymphoma (B-NHL)" ], "interventions": [ { "name": "Odronextamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 515, "start_date": "2019-11-13", "completion_date": "2028-12-15", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-09T19:40:29.135Z", "location_count": 13, "location_summary": "Chicago, Illinois • Iowa City, Iowa • Louisville, Kentucky + 9 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03888105" }, { "nct_id": "NCT01866839", "title": "Preventing Stem Cell Transplant Complications With a Blood Separator Machine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "MDS (Myelodysplastic Syndrome)", "Myeloproliferative Disorder", "Lymphoma, Non-Hodgkin", "ALL (Acute B-Lymphoblastic Leukemia)", "AML (Acute Myelogenous Leukemia" ], "interventions": [ { "name": "Graft Manipulation (CD34+ Selection)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "2 Years to 80 Years" }, "enrollment_count": 41, "start_date": "2013-05-29", "completion_date": "2018-06-28", "has_results": true, "last_update_posted_date": "2020-07-21", "last_synced_at": "2026-10-09T19:40:29.135Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01866839" }, { "nct_id": "NCT00445341", "title": "Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Flavopiridol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2006-11-27", "completion_date": "2012-10-18", "has_results": true, "last_update_posted_date": "2018-01-30", "last_synced_at": "2026-10-09T19:40:29.135Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00445341" }, { "nct_id": "NCT04116437", "title": "Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Zanubrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2019-10-15", "completion_date": "2026-01-09", "has_results": false, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-10-09T19:40:29.135Z", "location_count": 24, "location_summary": "Aurora, Colorado • Newark, Delaware • Fort Myers, Florida + 21 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Newark", "state": "Delaware" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04116437" }, { "nct_id": "NCT06151730", "title": "Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Lymphocytic Leukemia", "Hematopoietic and Lymphoid System Neoplasm", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Non-Interventional Study", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 100, "start_date": "2024-01-05", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-09T19:40:29.135Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06151730" }, { "nct_id": "NCT04450069", "title": "CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory B-cell Lymphomas", "Diffuse Large B Cell Lymphoma (DLBCL)", "Follicular Lymphoma (FL)", "Chronic Lymphocytic Leukemia (CLL)", "Marginal Zone Lymphoma (MZL)", "Mantle Cell Lymphoma", "Small Lymphocytic Lymphoma (SLL)", "Primary Mediastinal Large B Cell Lymphoma", "Transformed Follicular Lymphoma", "Waldenstrom Macroglobulinemia", "Lymphoplasmacytic Lymphoma", "Burkitt Lymphoma" ], "interventions": [ { "name": "CLBR001 and SWI019", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Calibr, a division of Scripps Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2020-08-14", "completion_date": "2024-05-06", "has_results": false, "last_update_posted_date": "2024-08-20", "last_synced_at": "2026-10-09T19:40:29.135Z", "location_count": 8, "location_summary": "Duarte, California • San Diego, California • Chicago, Illinois + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04450069" }, { "nct_id": "NCT06768905", "title": "IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Hodgkin Lymphoma", "Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "Iomab-B", "type": "DRUG" }, { "name": "CAR-T cell", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-04-25", "completion_date": "2030-05", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-09T19:40:29.135Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06768905" }, { "nct_id": "NCT04416451", "title": "A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Marginal Zone Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2021-05-04", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-10-09T19:40:29.135Z", "location_count": 8, "location_summary": "Duarte, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04416451" }, { "nct_id": "NCT00004105", "title": "Combination Chemotherapy in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Sarcoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "estramustine phosphate sodium", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "vinorelbine ditartrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-03-28", "last_synced_at": "2026-10-09T19:40:29.135Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004105" }, { "nct_id": "NCT00052572", "title": "Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "ixabepilone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2002-10", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2013-06-24", "last_synced_at": "2026-10-09T19:40:29.135Z", "location_count": 2, "location_summary": "New York, New York • Burlington, Vermont", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT00052572" } ] }